FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FENNEC PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$10.27+0.29 (+2.91%)
Close on Oct 19, 2026
- Market cap
- $374.14M
- P/E (TTM)
- –
- Dividend yield
- –
FENNEC PHARMACEUTICALS INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| PEDMARK | $44.64M | $29.58M | $21.25M | $1.54M | – | – | 100.0% | +50.9% |
| Royalty | – | – | – | – | $170.00K | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Fennec Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.